Systemic Sclerosis Mouse Study of Nintedanib in Fibrotic and Vascular Manifestations Looks Promising

Author: Daniela Semedo
Date Published: February-2016
Source: Scleroderma News

Nintedanib (OFEV) seems to inhibit the activation of fibroblasts and to exert an anti-fibrotic effect in mouse models of systemic sclerosis (SSc), according to data recently presented at the 4th Systemic Sclerosis World Congress in Lisbon, Portugal, last week. The presentation, “Effects of Nintedanib on Fibrotic and Vascular Manifestation in Pre-clinical Models of Systemic Sclerosis,” was given by J. Distler from the Department of International Medicine 3 and the Institute for Clinical Immunology at the University of Erlangen-Nuremberg in Germany.